Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease
Status:
Recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
This study is a Phase 3, randomized, double-blind, placebo-controlled study of voxelotor in
pediatric participants, aged ≥ 2 to < 15 years old, with Sickle Cell Disease. The primary
objective is to evaluate the effect of voxelotor on the TCD (Transcranial Doppler Ultrasound)
measurements in SCD participants in this age range.